Cyclacel announces dosing of first patient in phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes

Next-generation cdk2/9 inhibitor fadraciclib to be evaluated as a single agent and in combinations in streamlined, registration-directed study next-generation cdk2/9 inhibitor fadraciclib to be evaluated as a single agent and in combinations in streamlined, registration-directed study
CYCC Ratings Summary
CYCC Quant Ranking